key: cord-0900654-zz350ohy authors: Muralidar, Shibi; Ambi, Senthil Visaga; Sekaran, Saravanan; Krishnan, Uma Maheswari title: The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2 date: 2020-09-22 journal: Biochimie DOI: 10.1016/j.biochi.2020.09.018 sha: 6a86f3c83d4c9dbebd8703abaa149a2f6cb82714 doc_id: 900654 cord_uid: zz350ohy An acute respiratory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that surfaced in China in late 2019, continues to spread rapidly across the globe causing serious concerns. The coronavirus disease 2019 (COVID-19) is declared as a public health emergency worldwide by the World Health Organization (WHO). Increasing evidences have demonstrated human-to-human transmission that primarily affects the upper respiratory tract followed by lower respiratory tract damage leading to severe pneumonia. Based on the current status, the elderly population and people with prior co-morbidities are highly susceptible to serious health effects including cytokine up-regulation and acute respiratory distress syndrome (ARDS). Currently, COVID-19 research is still in the preliminary stage necessitating rigorous studies. There is no specific drug or vaccine targeting SARS-CoV-2 currently and only symptomatic treatment is being administered, but several antivirals are under active investigation. In this review, we have summarized the epidemiology, entry mechanism, immune response, and therapeutic implications, possible drug targets, their ongoing clinical trials, and put forward vital questions to offer new directions to the COVID-19 research. (54%) when compared to females (2.6%). ACE2 gene expression was also found to be higher in 194 smokers when compared to non-smokers. Few studies suggested that smoking history may play 195 an additional role in susceptibility of smokers towards COVID-19 infection [21, 22] . Some patients despite being asymptomatic or with minimum symptoms have reduced pulse 242 oximetry readings. This condition has been referred to as "Silent" or "apathetic hypoxia" [38- The patients turned to be non-responders to therapy and were reported dead at different days of immunoglobulins are yet to be discovered for both prevention and treatment of COVID-19. There are still many unresolved questions on SARS-CoV-2 that warrant investigation. Some of 580 the key questions that remain unresolved are: It has been reported that COVID-19 can be spread from asymptomatic persons. Quantitative It has been widely reported by many researchers and clinicians that older people are more The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Therapeutic strategies in an outbreak Epidemiological and clinical characteristics of 99 cases 678 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Coronavirus COVID-19 Outbreaks Outside China WHO Situation Report -3, Novel Coronavirus ( 2019-nCoV ), (2020) Candidate targets for immune responses to 2019-Novel Coronavirus 687 (nCoV): sequence homology-and bioinformatic-based predictions Research and Development on Therapeutic Agents 691 and Vaccines for COVID-19 and Related Human Coronavirus Diseases A novel coronavirus 695 from patients with pneumonia in China Coronavirus infections and immune responses Coronavirus infections Epidemiological , clinical and immunological features and hypotheses Features, Evaluation 704 and Treatment Coronavirus (COVID-19), StatPearls COVID-19: the gendered impacts of the outbreak Sars-cov-2 709 and coronavirus disease 2019: What we know so far The novel coronavirus 2019 ( 712 2019-nCoV ) uses the SARS-coronavirus receptor ACE2 and the cellular protease 713 TMPRSS2 for entry into target cells Emergence of novel coronavirus 2019-715 nCoV: Need for rapid vaccine and biologics development Return of the coronavirus: 2019-nCoV The transmission and diagnosis of 2019 novel coronavirus infection 735 disease (COVID-19): A Chinese perspective COVID-19 and the cardiovascular system Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins Trafficked pangolins can carry coronaviruses closely related to pandemic strain The coronavirus 2019-nCoV epidemic: Is 745 hindsight 20/20? The SARS-CoV-2 outbreak: what we know Airborne Transmission of SARS-CoV-2 Theoretical Considerations 750 and Available Evidence Clinical features of 754 patients infected with 2019 novel coronavirus in Wuhan, China COVID-19 patients with respiratory failure: what can we learn 757 from aviation medicine? Acute Respiratory Distress Syndrome Silent hypoxia: A harbinger of clinical 762 deterioration in patients with COVID-19 Clinical course and 770 risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a 771 retrospective cohort study COVID-19 pneumonia: different respiratory treatments for different phenotypes? Acute respiratory failure in COVID-19: is it "typical" ARDS? Excess Out-Of-Hospital Mortality and Declining Oxygen Saturation: The 780 Sentinel Role of EMS Data in the COVID-19 Crisis Functional assessment of cell entry and receptor usage 783 for SARS-CoV-2 and other lineage B betacoronaviruses Evidence for a Common Evolutionary Origin of Coronavirus Spike Protein 786 Receptor-Binding Subunits Human 816 immunopathogenesis of severe acute respiratory syndrome (SARS) Expression profile of immune response genes in patients with severe acute respiratory 820 syndrome 822 Characterization of cytokine/chemokine profiles of seven acute respiratory syndrome Yeast based small molecule screen for inhibitors of SARS-CoV Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic 830 Domain Regulate Antagonism of IRF3 and NF-κB Signaling Recognition of double-stranded 833 RNA and activation of NF-κB by Toll-like receptor 3 Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-984 converting enzyme isoforms in rats with experimental heart failure Evidence against a major role for 987 angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide 988 metabolism in the human coronary circulation Effects of captopril related to increased levels of prostacyclin and angiotensin Kidney and Lung ACE2 Expression 994 after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19 Unravelling an Unclear Relationship Aldosterone System Blockers and the Risk of Covid-19 Compounds with therapeutic potential against novel respiratory 2019 1003 coronavirus Analysis of therapeutic targets for SARS-CoV-2 and discovery 1007 of potential drugs by computational methods Human transbodies that interfere with the functions of Ebola virus VP35 protein in 1011 genome replication and transcription and innate immune antagonism article Pharmacologic Treatments for 1014 COVID-19): A Review Structural basis of influenza virus fusion inhibition by the 1017 antiviral drug Arbidol Host cell proteases: Critical determinants of coronavirus 1020 tropism and pathogenesis Middle East 1023 respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets SARS: Systematic review of treatment effects A randomized, controlled trial of Ebola virus disease therapeutics Therapeutic strategies for 1043 critically ill patients with COVID-19 Review of Emerging Pharmacotherapy for the Treatment of Coronavirus 1047 Disease Therapeutic Drugs Treating COVID-19 ongoing clinical trials An overview of 1056 severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: 1057 Peptidomimetics and small molecule chemotherapy lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings LopinavirRitonavir: A review of its use in the management of 1064 HIV-1 infection SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway 1068 through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6 P53 degradation by a coronavirus papain-like protease suppresses type I interferon 1072 signaling SARS coronavirus papain-like 1075 protease inhibits the type I interferon signaling pathway through interaction with the